And in return for spending that money - for taking all those risks - they get to have a monopoly that lasts for years and that allows them to sell their medications for lots of money and keep those prices high.Īnd there are actually laws and regulations that protect that monopoly. So the way the system works is we rely on for-profit companies to spend a lot of money to develop and bring to market new drugs. So we all know that prices are really high for many drugs in the United States. And you’ve been reporting on a case involving a big name American drug company. So Rebecca, you report on the pharmaceutical industry. Today, my colleague, Rebecca Robbins, on a case that suggests they can also create perverse incentives to hold new drugs back. sabrina taverniseįrom “The New York Times,” I’m Sabrina Tavernise, and this is “The Daily.”įor decades, drug companies have argued that patents are critical to bringing new drugs to market. Please review the episode audio before quoting from this transcript and email with any questions. While it has been reviewed by human transcribers, it may contain errors. This transcript was created using speech recognition software. Transcript Why One Drug Company Held Back a Better Drug Drug companies say patents spur innovation.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |